Abstract
The primary pathology of the human central nervous system disease multiple sclerosis (MS) and the animal counterpart experimental autoimmune encephalomyelitis (EAE) includes immunological and inflammatory events. Immune system involvement in MS has been widely debated but the role of inflammation has received less attention. Classic acute inflammation features vasculitis, resident tissue macrophage and mast cell participation plus the involvement of circulatory-derived neutrophils and platelets. Pre-lesion development in MS incorporates cerebral vasculitis, activated resident microglia in normal appearing white matter together with infiltrating cell types and factors indicative of an acute inflammatory reaction. Similarly, the formation of perivascular lesions during early EAE includes characteristic neurovasculitis, the participation of central nervous system microglial phenotypes plus haemopoietic cells and mediators, signifying an ongoing acute inflammatory response. EAE has been extensively used as a screen to select drugs for MS treatment but has been criticised as unrepresentative of the human condition due to fundamental differences in disease induction and pathogenesis. The review provides compelling evidence for a distinct acute inflammatory phase in MS lesion formation that is convincingly reproduced in early EAE pathology. Moreover, consideration of drug efficacy studies undertaken during initial EAE validates the occurrence of an acute inflammatory phase in disease pathogenesis. Critical appraisal, recognition and acceptance of the mutual acute inflammatory components inherent in the primary pathology of MS and EAE reveals new targets and encourages confident and reliable employment of the animal model in the assessment of novel compounds for the control of key primary pathological events in human demyelinating disease.
Keywords: Acute inflammation, EAE-targeted drugs, endothelial cells, experimental autoimmune encephalomyelitis, mast cells, microglia, multiple sclerosis, neutrophils, platelets.
CNS & Neurological Disorders - Drug Targets
Title:Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Volume: 14 Issue: 7
Author(s): Christopher Bolton and Paul Smith
Affiliation:
Keywords: Acute inflammation, EAE-targeted drugs, endothelial cells, experimental autoimmune encephalomyelitis, mast cells, microglia, multiple sclerosis, neutrophils, platelets.
Abstract: The primary pathology of the human central nervous system disease multiple sclerosis (MS) and the animal counterpart experimental autoimmune encephalomyelitis (EAE) includes immunological and inflammatory events. Immune system involvement in MS has been widely debated but the role of inflammation has received less attention. Classic acute inflammation features vasculitis, resident tissue macrophage and mast cell participation plus the involvement of circulatory-derived neutrophils and platelets. Pre-lesion development in MS incorporates cerebral vasculitis, activated resident microglia in normal appearing white matter together with infiltrating cell types and factors indicative of an acute inflammatory reaction. Similarly, the formation of perivascular lesions during early EAE includes characteristic neurovasculitis, the participation of central nervous system microglial phenotypes plus haemopoietic cells and mediators, signifying an ongoing acute inflammatory response. EAE has been extensively used as a screen to select drugs for MS treatment but has been criticised as unrepresentative of the human condition due to fundamental differences in disease induction and pathogenesis. The review provides compelling evidence for a distinct acute inflammatory phase in MS lesion formation that is convincingly reproduced in early EAE pathology. Moreover, consideration of drug efficacy studies undertaken during initial EAE validates the occurrence of an acute inflammatory phase in disease pathogenesis. Critical appraisal, recognition and acceptance of the mutual acute inflammatory components inherent in the primary pathology of MS and EAE reveals new targets and encourages confident and reliable employment of the animal model in the assessment of novel compounds for the control of key primary pathological events in human demyelinating disease.
Export Options
About this article
Cite this article as:
Bolton Christopher and Smith Paul, Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis, CNS & Neurological Disorders - Drug Targets 2015; 14 (7) . https://dx.doi.org/10.2174/1871527314666150716103629
DOI https://dx.doi.org/10.2174/1871527314666150716103629 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Novel Treatments in Subarachnoid Hemorrhage
The current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
Role of glial cells in autism spectrum disorder: Molecular mechanism and therapeutic approaches
Emerging evidence suggests that glial cells may play a pivotal role in neuroanatomical and behavioral changes found in autism spectrum disorder (ASD). Many individuals with ASD experience a neuro-immune system abnormalities throughout life, which implicates a potential role of microglia in the pathogenesis of ASD. Dysfunctional astrocytes and oligodendrocytes were ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews FDG-PET Imaging in Large Vessel Vasculitis and Polymyalgia Rheumatica: A Personal View
Current Immunology Reviews (Discontinued) Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Panniculitis: A Cardinal Sign of Autoinflammation
Current Rheumatology Reviews Alpha-1 Antitrypsin: It’s Role in Health and Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Painful Peripheral Neuropathies
Current Neuropharmacology Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research ATP-Sensitive Potassium Channel Modulators and Cardiac Arrhythmias: An Update
Current Pharmaceutical Design Targeting TNF-Alpha in HIV-1 Infection
Current Drug Targets Transcription Factors in Autoimmune Diseases
Current Pharmaceutical Design Editorial [Hot Topic: New Therapeutic Options in Central Nervous System Involvement of Rheumatologic Diseases (Executive Editor: Ali Gur)]
Current Pharmaceutical Design Targeting MET Receptor in Rhabdomyosarcoma: Rationale and Progress
Current Drug Targets The Involvement of Norepinephrine in Behaviors Related to Psychostimulant Addiction
Current Neuropharmacology Soluble RAGE-Modulating Drugs: State-of-the-Art and Future Perspectives for Targeting Vascular Inflammation
Current Vascular Pharmacology Alpha 1 Anti-Trypsin: One Protein, Many Functions
Current Molecular Medicine Anti Citrullinated Protein Antibodies and Mechanism of Action of Common Disease Modifying Drugs - Insights in Pathomechanisms of Autoimmunity
Current Pharmaceutical Design Update on the Principles and Novel Local and Systemic Therapies for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Cardiac MRI in Autoimmune Diseases: Where Are We Now?
Current Cardiology Reviews